Top Links

Articles Related to Cancers

Former Effective Immunotherapy without Adverse Events of Inoperable Epithelial Ovarian Cancers and a Prospect for the Immune Prophylaxis

Current cancer treatments by immune checkpoint blockades are limited due to severe adverse events caused by alteration of the immune system required for homeostasis of normal tissues. Common cancer chemotherapy alters the quality of patients’ lives. Platinum-based treatment can lead to severe neurotoxicity with chronic debilitation. Additionally, survival of patients with epithelial ovarian cancers (EOCs) has remained poor despite extensive cytoreductive surgery, high dose chemotherapy, checkpoint blockades and immunotherapies effective in some other types of cancer. The pathobiology of EOC cancer stem cells (CSCs) is not well understood. Observations demonstrate that EOCs exhibit in vivo two distinct CSC types - perivascular diploid CSCs dividing asymmetrically with the help of the host suicidal CD8+ T cells, and haploid CSCs at the cancer abdominal surface originating from meiosis I cytokinesis of bulk surface cancer cells. The perivascular CSCs contribute to the cancer cell bulk and, via left ovary venous blood, can cause EOC liver metastases. Haploid CSCs released from the bulk cancer surface cause the common pelvic and abdominal EOC spread. Former elimination of the host antibodies blocking T cell effectors by intermittent doses of cyclophosphamide exhibiting significant immunomodulatory anticancer effects, facilitation of the immune system reactivity against alloantigens of cancer cells by blood transfusions, and augmentation of anticancer immunity by bacterial toxins, resulted during the subsequent treatment-free period into rejection of inoperable EOCs without any adverse events during the treatnment. To help prevent cancer relapses, patients treated for advanced primary epithelial cancers should be considered as candidates for continuously stimulating immune anticancer activity by treatments such as daily metformin and weekly lentinan consumptions.
View complete article: PDF  |  Full-text

Paediatric Radiotherapy in Morocco

In Morocco, through the finding of the Casablanca population-based registry, all cancers are estimated at 35000 new cases par year and 3.2% are aged less or equal 20 years.
View complete article: PDF  |  Full-text

Lip Cancer: Epidemiologic, Clinical, Evolutive, and Therapeutical Aspects

Lip cancer is relatively common, despite the progress seen recently in Morocco in terms of labial-jugal cancer reconstructions. Lip cancer is often seen in advanced stages and poses management problems.
View complete article: PDF  |  Full-text

Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites

Ovarian cancer constitutes the second most common gynecological cancer with a five-year survival rate of 40%. Among the various histotypes associated with hereditary ovarian cancer, high-grade serous epithelial ovarian carcinoma (HGSEOC) is the most predominant and women with inherited mutations in BRCA1 have a lifetime risk of 40-60%. HGSEOC is a challenge for clinical oncologists, due to late presentation of patient, diagnosis and high rate of relapse. Ovarian tumors have a wide range of clinical presentations including development of ascites as a result of deregulated endothelial function thereby causing increased vascular permeability of peritoneal vessels.
View complete article: PDF  |  Full-text


Editorial Board Members Related to Cancers

AARON P. THRIFT

Assistant Professor
Department of Medicine
University of Baylor College of Medicine
United States

VEENA N. RAO

Professor
Department of Obstetrics and Gynecology
Morehouse School of Medicine
Georgia Cancer Center for excellence
United States

Xiaoqing Guo

Division of Genetic and Molecular Toxicology
National Center for Toxicological Research (NCTR)
USA

CHI-HIN CHO

Professor
School of Biomedical Sciences
The Chinese University of Hong Kong
Hong Kong
China

Nallasivam Palanisamy

Associate Professor
Michigan Center for Translational Pathology
University of Michigan
United States

Yu Shyr

Professor
Department of Biomedical Informatics
Vanderbilt University
United States

PREET M. CHAUDHARY

Professor
Department of Medicine
University of Southern California
United States

Farrukh Aqil

Assistant professor
Department of medicine
University of louisville
United States

Steve A. Maxwell

Associate Professor
Department of Molecular and Cellular Medicine
Texas A&M Health Science Center
United States

Kam C. Yeung

Associate Professor
Department of Biochemistry & Cancer Biology
University of Toledo College of Medicine
United States
Submit Manuscript